Skip to content

Molecular Mechanisms and Clinical Translation of GSTM3-Regulated Lipid Metabolic Reprogramming for the Treatment of Non-Alcoholic Fatty Liver Disease

Molecular Mechanisms and Clinical Translation of GSTM3-Regulated Lipid Metabolic Reprogramming for the Treatment of Non-Alcoholic Fatty Liver Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500115090
Enrollment
Unknown
Registered
2025-12-22
Start date
2026-01-01
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic fatty liver disease

Interventions

Case group:None
Control group:None

Sponsors

The Affiliated Hospital of Guangdong Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Case Group: 1. Aged 18 years or older; 2. Patients meeting surgical indications related to liver diseases (primary liver cancer, liver metastases, hepatic hemangioma, liver cysts, hepatobiliary stones, end-stage liver disease, etc.); 3. Patients diagnosed with non-alcoholic fatty liver disease (NAFLD). Control Group: 1. Aged 18 years or older; 2. Patients meeting surgical indications related to liver diseases (primary liver cancer, liver metastases, hepatic hemangioma, liver cysts, hepatobiliary stones, end-stage liver disease, etc.); 3. Patients without non-alcoholic fatty liver disease (NAFLD).

Exclusion criteria

Exclusion criteria: Case Group: 1. Patients with severe diseases of important organs such as the heart, lungs, kidneys, or brain, or other malignant tumors: these conditions may affect survival risk, thereby interfering with the accuracy of the model's predictions; 2. Pregnant or breastfeeding women: the physiological and pathological conditions during pregnancy and breastfeeding may be special, and for ethical considerations, such patients are usually excluded. Control Group: 1. Patients with severe diseases of important organs such as the heart, lungs, kidneys, or brain, or other malignant tumors: these conditions may affect survival risk, thereby interfering with the accuracy of the model's predictions; 2. Pregnant or breastfeeding women: the physiological and pathological conditions during pregnancy and breastfeeding may be special, and for ethical considerations, such patients are usually excluded; 3. Patients diagnosed with non-alcoholic fatty liver disease (NAFLD).

Design outcomes

Primary

MeasureTime frame
Change in liver fat content;Liver function indicators;Degree of hepatic inflammatory activity;GSTM3 expression level;

Countries

China

Contacts

Public ContactYuping Yang

The Affiliated Hospital of Guangdong Medical University

yangyupingchn@163.com+86 13535067921

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026